Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Pemphigoid; Stevens-Johnson syndrome; Toxic epidermal necrolysis
- Focus Adverse reactions
- 05 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment as No patients met eligibility criteria.
- 03 Apr 2017 Planned End Date changed from 1 Mar 2017 to 3 Apr 2017.
- 02 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.